2016-04-28 13:49:06 UTC
April 27, 2016
The study, which is being led by Shire, is set to finish in July 2018.
A new, phase 3 trial is investigating the effects of the oral steroid budesonide on eosinophilic esophagitis (EoE) in adolescent and adult patients.
The randomized, double-blind trial, led by Shire, is taking place at approximately 60 sites throughout the U.S. and is currently enrolling 300 subjects. Subjects will receive 10 mL of 0.2 mg/mL (2 mg) of the budesonide oral suspension or the placebo every morning and at bedtime over a 16-week treatment period. The study is set to finish in July 2018.